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Integrin-dependent Control of Translation: Engagement of Integrin aIIbb3
Regulates Synthesis of Proteins in Activated Human Platelets
Ravinder Pabla,* Andrew S. Weyrich,*i Dan A. Dixon,‡ Paul F. Bray,** Thomas M. McIntyre,*i¶
Stephen M. Prescott,‡§i and Guy A. Zimmerman*i
*Nora Eccles Harrison Cardiovascular Research and Training Institute, ‡Program in Human Molecular Biology and Genetics,
Eccles Institute of Human Genetics, §Department of Biochemistry, iDepartment of Internal Medicine, and ¶Department of
Pathology, University of Utah, Salt Lake City, Utah 84112; and the **Department of Medicine, Johns Hopkins University
School of Medicine, Baltimore, Maryland 21205

Abstract. Integrins are widely expressed plasma membrane adhesion molecules that tether cells to matrix
proteins and to one another in cell–cell interactions. Integrins also transmit outside-in signals that regulate
functional responses of cells, and are known to influence gene expression by regulating transcription. In
previous studies we found that platelets, which are naturally occurring anucleate cytoplasts, translate preformed mRNA transcripts when they are activated by
outside-in signals. Using strategies that interrupt engagement of integrin aIIbb3 by fibrinogen and platelets
deficient in this integrin, we found that aIIbb3 regulates
the synthesis of B cell lymphoma 3 (Bcl-3) when platelet aggregation is induced by thrombin. We also found
that synthesis of Bcl-3, which occurs via a specialized
translation control pathway regulated by mammalian

I

are plasma membrane proteins that mediate
adhesion of cells to other cells and to matrix structures (Hynes, 1992). Individual a and b subunits pair
to form heterodimers of characteristic ligand specificity
that interact via their cytoplasmic domains with cytoskeletal and other intracellular proteins (Hynes, 1992; Shattil
and Ginsberg, 1997). Interaction of integrin intracellular
domains with cytoplasmic proteins confers the ability to
transmit outside-in signals when the extracellular domains
are engaged by specific ligands, in addition to providing a
mechanism by which affinity and avidity of integrins for
their ligands can be regulated (Hynes, 1992; Clark and
Brugge, 1995; Schwartz et al., 1995; Shattil and Ginsberg,

target of rapamycin (mTOR), is induced when platelets
adhere to immobilized fibrinogen in the absence of
thrombin and when integrin aIIbb3 is engaged by a conformation-altering antibody against integrin aIIbb3.
Thus, outside-in signals delivered by integrin aIIbb3 are
required for translation of Bcl-3 in thrombin-stimulated
aggregated platelets and are sufficient to induce translation of this marker protein in the absence of thrombin. Engagement of integrin a2b1 by collagen also triggered synthesis of Bcl-3. Thus, control of translation
may be a general mechanism by which surface adhesion
molecules regulate gene expression.
Key words: adhesion • integrins • platelets • translation • gene regulation
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1997). Outside-in signaling resulting from integrin engagement triggers a variety of responses in cells, including
fluxes in intracellular calcium, sodium–proton exchange
and alterations in intracellular pH, phosphatidylinositol
metabolism, activation of calpain, focal adhesion kinase,
mitogen-activated protein kinases and other enzymes,
and induction of nuclear signaling pathways leading to expression of new gene products (Clark and Brugge, 1995;
Schwartz et al., 1995; Howe et al., 1998). These biochemical events lead to both rapid and delayed changes in cellular function and phenotype, including motility, growth,
and differentiation. Outside-in signaling by integrins is
both heterodimer- and cell-specific (Shattil and Ginsberg,
1997) and has been studied frequently in the context of adhesion of cells to matrix ligands. Although integrins are
also prototypic tethering factors in cell–cell interactions
(Zimmerman et al., 1996), less is known of their outside-in
signaling roles in this context compared with cell–matrix
interactions.
The mechanisms by which gene expression is regulated
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by cellular adhesion are of considerable interest because
this imposes both spatial and biochemical control on the
process. Studies of fibroblasts and human monocytic cells
demonstrate that engagement of integrins by antibodies
against their extracellular domains or by matrix ligands induces activation and/or nuclear translocation of Rel (NF-kB)
and other transcription factors, and consequent transcription of specific mRNAs (Schwartz et al., 1995; Juliano,
1996). In some cases, only mRNA transcripts are induced
by integrin engagement alone, and a second signal is required for their translation and expression of the corresponding protein (Juliano, 1996). Whether integrins directly or indirectly regulate posttranscriptional pathways
is largely unknown, and is a challenging issue to study because of the clear and potent influence of integrin engagement on transcriptional events (Juliano and Haskill, 1993;
Schwartz et al., 1995).
Recently, we found that stimulated human platelets synthesize proteins from preformed mRNA in an activationdependent fashion (Weyrich et al., 1998). Because they are
primary anucleate cytoplasts that bear receptors and surface adhesion molecules capable of mediating outside-in
signaling (Shattil et al., 1994, 1998), platelets are a unique
system in which to study activation-dependent translational events independent of nuclear influences. In activated platelets, the synthesis of several induced proteins is
inhibited by the immunosuppressant rapamycin in addition to general inhibitors of translation (Weyrich et al.,
1998), indicating the presence of a specialized pathway of
translational control regulated by mammalian target of rapamycin (mTOR)1 (Brown and Schreiber, 1996; Thomas
and Hall, 1997). The transcript for B cell lymphoma protein 3 (Bcl-3), an intracellular regulatory factor, is present
in platelets and is translated via this pathway when platelets are stimulated with thrombin (Weyrich et al., 1998),
making it a useful marker for studies of regulated protein
synthesis in this cell type. Here we show that translation of
Bcl-3 is an adhesion-dependent event that requires engagement of integrin aIIbb3 in platelets activated by thrombin. Integrin aIIbb3 is expressed only by platelets and
megakaryocytes, and transmits outside-in signals in addition to mediating cellular aggregation and adhesion (Phillips et al., 1991; Hynes, 1992; Shattil et al., 1998). We also
show that direct engagement of integrin aIIbb3 induces expression of Bcl-3 in the absence of thrombin or other exogenous agonists, and that synthesis of Bcl-3 is induced
when platelets adhere to collagen via integrin a2b1. These
experiments demonstrate for the first time that integrins
can directly control expression of gene products at translational checkpoints, and that their influence on the flow of
genetic information is not limited to regulation of transcription.

(1990). In brief, human blood was drawn into acid-citrate-dextrose (ACD;
7 ml ACD/42 ml of blood) and was centrifuged (200 g for 20 min) to obtain platelet-rich plasma. Platelet-rich plasma was recentrifuged (500 g for
20 min) in the presence of 100 nM prostaglandin E-1. The supernatant was
discarded and platelet pellet was resuspended in 50 ml of Pipes/saline/glucose (5 mM Pipes, 145 mM NaCl, 4 mM KCl, 50 mM Na2HPO4, 1 mM
MgCl2-6 H2O, and 5.5 mM glucose), containing 100 nM of prostaglandin
E-1 (Sigma Chemical Co.). The platelet suspension was centrifuged (500 g
for 20 min), the supernatant was discarded, and the platelet pellet was resuspended in M199 (phenol red free; Whittaker M.A. Bioproducts). In selected studies, the platelets were suspended in Ca21 and Mg21-free HBSS
containing 5 mM EGTA to chelate Ca21. 2.5 3 108 platelets were used for
each experimental point. Platelets were stimulated with thrombin (Sigma
Chemical Co.), collagen (from human placenta; Sigma Chemical Co.), fibrinogen (Sigma Chemical Co.), or an activating antibody, D3GP3 (provided by Dr. L.K. Jennings, University of Tennessee, Memphis, TN) for 1 h
at 378C while gently rocking in small volume conical tubes. In selected
studies, platelets were preincubated with aIIbb3 blocking antibodies, 7E3
(obtained commercially and provided by Dr. S. Tam, Centocor, Malvern,
PA), 10E5 (provided by Dr. B.S. Coller, Mount Sinai School of Medicine,
New York), G4120, G4709 (provided by Dr. T. Gadek, Genentech, San
Francisco, CA), or integrilin (eptifibatide) (provided by Dr. S. Hollenbach, COR Therapeutics, South San Francisco, CA) before stimulation
with thrombin. Isotype-matched antibodies were used as controls as indicated in the text and figure legends (a-LFA-1 and CD31 from R&D Systems). After 1 h, the platelet pellets were collected and prepared for Western analysis as described below.
Human tissues for examination of platelets in situ were collected at the
time of surgical intervention. Surgical tissues were collected according to
protocols approved by the University of Utah internal review board after
informed consent.

Platelet Adhesion Assay
Platelet adhesion to fibrinogen was studied in 4-well polystyrene chambers (Nunc Inc.) precoated overnight at 48C with HBSS-human serum albumin (2%), which served as the control, fibrinogen (1 mg/ml; Sigma
Chemical Co.), or collagen (50 mg/ml; Sigma Chemical Co.). Plates were
washed three times and blocked for 2 h with 1 ml of HBSS-human serum
albumin (2%), and washed three times with HBSS followed by three more
washes with HBSS containing 0.01% Tween 20. Residual buffer was removed by aspiration and 2.5 3 108 platelets/ml were added to the matrixcoated wells for 1 h at 378C. After this time, adherent platelets were
scraped into Eppendorf tubes and the suspensions were centrifuged for 2
min, 1,000 g at room temperature, and the supernatants were removed.
The cell pellets were placed in SDS-PAGE reducing buffer for Western
analysis as described below.

Immunoblotting Procedure
Platelet pellets, collected from activated cells in suspension or those adherent to fibrinogen, were placed in SDS-PAGE reducing buffer, electrophoresed on a 9% SDS-polyacrylamide gel, and transferred to a nitrocellulose membrane. Western analysis was conducted using affinity-purified,
rabbit polyclonal anti–Bcl-3 antibody (Santa Cruz Technology). Immunoreactive protein was detected by affinity-isolated goat anti–rabbit antibody conjugated to peroxidase (Biosource Int.) and an enhanced chemiluminescence detection reagent (Amersham Life Science).

Immunocytochemical and
Immunohistochemical Procedures

1. Abbreviations used in this paper: Bcl-3, B cell lymphoma 3; mTOR,
mammalian target of rapamycin; PDK1, 3-phosphoinositide-dependent
protein kinase 1; PI3K, phosphatidylinositol-3-kinase.

Immunocytochemical procedures were performed as described previously, with minor modifications (Weyrich et al., 1996, 1998). In brief,
platelets were spun onto glass slides and immediately fixed with 1%
paraformaldehyde. After a methanol permeabilization step, the cells were
blocked and probed with anti–Bcl-3 (Santa Cruz Technology). Immunoreactive protein for Bcl-3 was detected using an ABC kit from Vectastain
(Vector Laboratories, Inc.) for horseradish peroxidase detection that
yields a brown immunostain product. Control slides included omission of
the primary antibody, omission of the secondary antibody, and/or substitution of nonimmune rabbit IgG. Tissue specimens from abdominal aortic
aneurysms were collected and placed in Histochoice MB fixative (Amresco Inc.). After fixation, the specimens were embedded in paraffin, sectioned into 5-mm slices, and immunoreactivity for Bcl-3 was assayed as de-
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Materials and Methods
Cell Isolation
Platelets were isolated using the methods of Hamburger and McEver

Figure 1. Bcl-3 is expressed
in aggregated human platelets activated by thrombin.
Platelets (2.5 3 108/ml) were
isolated as described (Materials and Methods) and
treated with control buffer or
thrombin (0.1 U/ml) for 1 h
at 378C while being gently
rocked in small volume conical tubes. Immunostaining
using an antibody against
Bcl-3 was done as described
(Materials and Methods; Weyrich et al., 1998). (A) Platelets treated with buffer alone remained single with little or no staining by anti–
Bcl-3 when viewed by low power or high power (not shown) microscopy. (B) Large multicellular aggregates formed in response to
thrombin with smaller aggregates also visible and few single cells remaining in suspension. The aggregates stained intensely for Bcl-3,
obscuring individual cellular detail at low power. (C) Pretreatment with the blocking anti-aIIbb3, mAb 10E5 (see text), dramatically inhibited platelet aggregation and staining for Bcl-3. As shown, in some experiments inhibition of aggregation was not complete and Bcl- 3
protein was present in the scattered small residual aggregates. The figures are representative of multiple experiments with thrombinstimulated platelets and of six experiments examining the effects of antiintegrin antibodies. Bar, 10 mm.

scribed previously (Weyrich et al., 1993). Sections were viewed and
photographed by Nomarski interference contrast optics using a Zeiss Axioplan light microscope. Tissue collection procedures were approved by
the University of Utah Institutional Review Board.

Aggregometry
0.5-ml aliquots of platelets (2.5 3 108/ml) were preincubated for 5 min at
378C in the presence of buffer or antibodies before aggregation was initiated by thrombin. Platelets were placed in siliconized cuvettes and aggregation was monitored by a Sienco aggregometer (model DP-247-E) with
constant stirring at 1,000 rpm at a constant temperature of 378C as described previously (Kouns et al., 1990).

ELISA
Concentrations of RANTES were measured by ELISA as described previously (Weyrich et al., 1996).

Results
The Expression of Bcl-3 Is Enhanced in Aggregated
Human Platelets
In previous experiments, we found that isolated human
platelets translate constitutively present mRNA into proteins in an activation-dependent fashion, that this occurs in
platelets stimulated with thrombin, and that Bcl-3 is an informative marker protein to examine in analyses of the
synthetic response in this system (Weyrich et al., 1998). In
addition, we found that when suspensions of thrombinstimulated platelets were stained using an antibody against
Bcl-3, expression of the protein appeared to be enhanced
in aggregated cells compared with single cells. This sugFigure 2. Bcl-3 is expressed
in aggregated human platelets in situ. Tissue sections
from vessels resected at the
time of surgical intervention
in patients with abdominal
aortic aneurysms were examined by immunohistochemical analysis. Bcl-3, indicated
by the brown reaction product, is present in intravascular platelet aggregates and in
platelets adherent to walls of
adventitial microvessels (arrows). The adventitia of aneurysmal vessels is an area of
inflammatory and thrombotic signaling and cell–cell
interactions (Modur et al.,
1997). Bcl-3 is also present in
endothelial cells and leukocytes in this section, consistent with in vitro observations (Ohno et al., 1990; Pan
and McEver, 1995). This figure is representative of surgical specimens from three different subjects. Bar, 10 mm.
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concentration-dependent (Fig. 3 and data not shown),
consistent with our earlier studies characterizing its synthesis in this cell type (Weyrich et al., 1998). Because aggregation of human platelets depends on engagement of
integrin aIIbb3 by fibrinogen or von Willebrand factor
(Gawaz et al., 1991; Williams et al., 1995), these observations suggested that outside-in signaling via this integrin
heterodimer regulates the synthetic pathway leading to expression of the Bcl-3 protein. Therefore, we characterized
the role of integrin aIIbb3 in detail.

Chelation of Extracellular Calcium Inhibits
Platelet–Platelet Clustering and Abolishes
Bcl-3 Synthesis

Figure 3. Removal of extracellular calcium prevents platelet aggregation and inhibits Bcl-3 synthesis. Platelets (2.5 3 108/ml)
were isolated as described in Materials and Methods, pretreated
for 30 min with vehicle or 5 mM EGTA, and then activated with
thrombin for 1 h. (a) Chelation of extracellular calcium abolished
platelet aggregation in response to thrombin. (b) In control platelets, thrombin induced Bcl-3 accumulation in a concentrationdependent fashion when assayed by Western analysis or immunostaining (not shown). The accumulation of Bcl-3 was inhibited
in platelets stimulated with thrombin in Ca 21-free buffer in the
presence of the chelator. (c) Thrombin triggered release of
RANTES by platelets pretreated with EGTA as well as by control platelets. These results are representative of seven independent experiments.

We determined if chelation of extracellular calcium interrupts Bcl-3 synthesis, since it is known to block platelet
aggregation (Fitzgerald et al., 1985; Shattil et al., 1985).
Platelets stimulated with thrombin in calcium-free buffer
containing EGTA (5 mM) did not aggregate in response
to thrombin (Fig. 3) and did not synthesize Bcl-3 (Fig. 3 b).
As a control to test whether signaling via the thrombin receptor was still intact under these conditions, we measured
the secretion of RANTES, a preformed chemokine that is
stored in alpha granules (Kameyoshi et al., 1992; Weyrich
et al., 1996), and found that it was released in response to
stimulation (Fig. 3 c). These findings suggested that disruption of adhesive interactions between the aggregating
platelets by removal of extracellular cations resulted in
impaired synthesis of Bcl-3. Alterations in cation concentrations also have the potential to inhibit intracellular
enzymes and other components required for protein synthesis, however, so we pursued this issue further using additional experimental strategies.

mAbs Directed Against Integrin aIIbb3 Inhibit Platelet
Aggregation and Bcl-3 Synthesis

gested that signaling of protein synthesis in stimulated
platelets is influenced by adhesion. To further explore this
issue we performed additional immunocytochemical analyses and found that Bcl-3 protein is rapidly expressed in
platelet aggregates after thrombin stimulation, with lesser
amounts in thrombin-stimulated single cells and little or
no protein detectable in platelets in the absence of thrombin (Fig. 1). When the anti–Bcl-3 antibody was deleted or
replaced with a control rabbit immunoglobulin, there was
no staining of Bcl-3 (Weyrich et al., 1998; data not shown).
We also found that Bcl-3 is present in aggregated platelets
in microvessels of inflamed tissue (Fig. 2), demonstrating
that its synthesis in isolated platelets (Fig. 1) models in
vivo events. The accumulation of Bcl-3 in thrombin-stimulated aggregated platelets examined in vitro was time- and

We next determined if engagement of the aIIbb3 integrin is
required for Bcl-3 synthesis in thrombin-stimulated platelets. Platelet aggregation occurs when aIIbb3 heterodimers
on adjacent activated platelets are engaged by fibrinogen
released from alpha granules or added exogenously (Gawaz
et al., 1991; reviewed in Williams et al., 1995). mAb 10E5
blocks binding of fibrinogen to aIIbb3 and prevents platelet
aggregation (Coller et al., 1983; Coller, 1985). Therefore,
we determined if mAb 10E5 inhibits Bcl-3 accumulation in
stimulated human platelets. As expected, preincubation of
platelets with mAb 10E5 markedly attenuated thrombininduced platelet aggregation compared with control cells
in the absence of antibody (Figs. 1 and 4). In addition, Bcl-3
accumulation was inhibited by pretreatment of platelets
with mAb 10E5 when examined by immunocytochemistry
(Fig. 1) and Western analysis (Fig. 4 b). In some incubations, there were scattered small residual aggregates that
were visible by microscopy in suspensions pretreated with
mAb 10E5 and then stimulated with thrombin, although
the majority of cells did not aggregate; these residual aggregates contained Bcl-3 when examined by immunocytochemical analysis (Fig. 1 c). An isotype-matched mAb
against aLb2 integrin (a-LFA-1; IgG2a) did not inhibit
Bcl-3 accumulation in thrombin-stimulated platelets or
block platelet aggregation (Fig. 4).
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(R) in the RGD sequence confers specificity for integrin
aIIbb3 compared with other integrins, and cyclic peptides
containing the KGD sequence that are based on the snake
venom disintegrin, barbourin, potently inhibit fibrinogen
binding to aIIbb3 and platelet aggregation (Scarborough et
al., 1991; Scarborough et al., 1993). We first examined linear RGD peptides as antagonists of aggregation-dependent Bcl-3 synthesis in human platelets and found that under some conditions the peptides themselves had weak
agonist effect (not shown), consistent with previous observations (Du et al., 1991). Then, we examined a cyclic KGD
heptapeptide that specifically binds to integrin aIIbb3 (Schulman et al., 1996; Pursuit Trial Investigators, 1998). The cyclic peptide antagonist inhibited both thrombin-induced
platelet aggregation (Fig. 5 a) and Bcl-3 accumulation (Fig.
5 b). The inhibition was concentration-dependent (range
1–10 mg/ml) with maximal inhibition at 10 mg/ml (Fig. 5 b).
A control peptide had no effect. A second blocking cyclic
peptide, G4120 (Barker et al., 1992), also inhibited Bcl-3
synthesis in a concentration-dependent fashion, whereas a
control peptide did not (not shown). Thus, inhibition of
engagement of aIIbb3 integrin with competitive peptides

Figure 4. An antibody that blocks engagement of integrin aIIbb3
inhibits stimulated synthesis of Bcl-3. Platelets were isolated, preincubated with control buffer, mAb 10E5 (IgG2a), or a control
isotype-matched mAb against integrin aLb2 (a-LFA-1) for 5 min
at 378C. They were then stimulated with thrombin or treated with
control buffer, and platelet aggregation and accumulation of Bcl-3
were examined in parallel as described in Materials and Methods
and Figs. 1 and 2. (a) mAb 10E5 inhibits aggregation of thrombin-stimulated platelets whereas anti-aLb2 did not. (b) mAb 10E5
inhibited accumulation of Bcl-3 in platelets stimulated with
thrombin in the concentrations shown for 1 h. The isotypematched control antibody did not attenuate Bcl-3 accumulation
compared with that in platelets treated with control buffer alone.
The results shown are representative of six independent events.

We performed similar experiments with the Fab fragment of the chimeric human-murine mAb 7E3. This antibody recognizes integrins aIIbb3 and avb3, inhibits fibrinogen binding to platelets, and has been used to block
platelet aggregation as a clinical antithrombotic agent (Coller, 1985; Reverter et al., 1996; Coller, 1997). mAb 7E3 attenuated Bcl-3 accumulation in thrombin-stimulated platelets and also inhibited aggregation in parallel incubations
(not shown). In contrast, a mAb against avb3 did not block
Bcl-3 expression.

Binding of fibrinogen to integrin aIIbb3 on activated platelets requires engagement of a dodecapeptide sequence in
the g chain of fibrinogen by the integrin heterodimer, an
event that can be blocked by peptides that contain arginine-glycine-asparagine (RGD) sequences (Du et al., 1991;
Phillips et al., 1991). Substitution of lysine (K) for arginine

Figure 5. A cyclic KGD peptide that specifically blocks engagement of integrin aIIbb3 inhibits Bcl-3 synthesis in thrombin-stimulated human platelets. Platelets were isolated as described in Materials and Methods, pretreated with a cyclic KGD heptapeptide
specific for integrin aIIbb3 or a control peptide (5 min at 378C),
and then activated with thrombin. (a) Thrombin-induced (0.1 U/ml)
platelet aggregation was inhibited when platelets were pretreated
with the cyclic KGD peptide (10 mg/ml) but not by a control peptide in an equivalent concentration. (b) Pretreatment of platelets
with the cyclic KGD peptide attenuated Bcl-3 synthesis in thrombin-activated platelets, whereas a control KGD peptide at the
same concentration did not. These results are representative of
four independent experiments.
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Peptides That Block Engagement of Integrin aIIbb3
Inhibit Synthesis of Bcl-3 in Stimulated
Human Platelets

attenuates accumulation of Bcl-3 in platelets stimulated
with thrombin (Fig. 5), as does treatment of the platelets
with blocking antibodies (Fig. 4).

Bcl-3 Synthesis Is Absent or Reduced When Platelets
Deficient in Integrin aIIbb3 Are Stimulated
with Thrombin
Platelets from patients with Glanzmann thrombasthenia
have significant reductions or absence of aIIbb3 on their
surfaces (George et al., 1990; Newman and Poncz, 1995).
The deficiency in integrin aIIbb3 prevents normal binding
of ligands and consequent platelet aggregation, accounting
for the hemostatic defect that characterizes these subjects.
Platelets from patients with Glanzmann thrombasthenia
also have impaired outside-in signaling (Wang et al.,
1997). We studied platelets from a patient with type I
Glanzmann thrombasthenia that do not aggregate when
stimulated by thrombin or a variety of other agonists (Jin
et al., 1996). When compared with platelets from a normal
control subject isolated in parallel, these mutant platelets
exhibited a dramatic defect in accumulation of Bcl-3 in response to thrombin stimulation (Fig. 6). There was no accumulation of Bcl-3 in the integrin aIIbb3-deficient platelets at concentrations of thrombin (0.05, 0.1 U/ml) that
induced synthesis of the protein marker in the simultaneously assayed control platelets (Fig. 6) or in platelets
from other control subjects (Figs. 1 and 3–5). At higher
concentrations of thrombin, accumulation of Bcl-3 in the
aIIbb3-deficient platelets was attenuated but not absent
(Fig. 6).

Direct Activation of Integrin aIIbb3 Induces
Bcl-3 Synthesis
We showed previously that adhesion of platelets to purified immobilized fibrinogen induces the synthesis of multiple proteins in the absence of thrombin or another agonist
(Weyrich et al., 1998). This is consistent with earlier studies indicating that integrin aIIbb3 on the platelet surface
can engage immobilized fibrinogen and transmit outsidein signals without requiring an exogenous agonist, whereas
engagement by soluble fibrinogen requires agonist-stimulated cellular activation (Savage and Ruggeri, 1991; Hai-

Figure 7. Engagement of integrin aIIbb3 by immobilized ligand or
an activating antibody induces synthesis of Bcl-3 in human platelets. (a) Adhesion of platelets to immobilized fibrinogen induces
synthesis of Bcl-3. Isolated platelets were incubated on an immobilized fibrinogen matrix or on immobilized albumin for 1 h at
378C and then examined for the accumulation of Bcl-3 by Western analysis as described in Materials and Methods and Fig. 3.
The fibrinogen matrix and control surface were prepared (Materials and Methods) using a modification of a previously described
method (Haimovich et al., 1993). This result is representative of
four experiments. (b) An activating antibody against integrin
aIIbb3, D3GP3, triggers synthesis of Bcl-3 in isolated human
platelets. Isolated platelets were incubated in suspension with
mAb D3GP3 (40 mg/ml), with fibrinogen (100 mg/ml), or with
mAb D3GP3 plus fibrinogen for 1 h at 378C and then processed
for Western analysis for Bcl-3 (Materials and Methods and Fig.
3). In parallel, platelets were treated with thrombin (0.1 U/ml) or
control buffer as positive and negative controls, respectively. In
contrast to mAb D3GP3 (third and fifth lanes), a control antibody did not trigger Bcl-3 accumulation (not shown). A second
experiment yielded similar results.

Figure 6. Platelets deficient in integrin aIIbb3 have absent or attenuated synthesis of Bcl-3 when stimulated with thrombin.
Platelets (2.5 3 108/ml) were isolated from a subject with Glanzmann thrombasthenia and from a control subject in parallel and
were stimulated with thrombin at the indicated concentrations
for 2 h at 378C. They were then assayed for Bcl-3 by Western
analysis as described in Materials and Methods and Fig. 3. Additional measurements indicated equivalent loading of protein in
samples of the control and aIIbb3 integrin–deficient platelets (not
shown).

movich et al., 1993; Shattil et al., 1994). To determine if
engagement of integrin aIIbb3 is sufficient to induce translation of the marker protein Bcl-3, we first used this immobilized fibrinogen system. We found that platelets adherent to a fibrinogen matrix accumulated Bcl-3 (Fig. 7 a). In
contrast, there was little or no Bcl-3 in platelets incubated
in suspension (not shown) or on immobilized albumin in
parallel. mAbs 10E5 and 7E3 (see above) inhibited Bcl-3
accumulation in platelets adherent to immobilized fibrinogen. In addition, LY 294002 and Wortmannin, which inhibit phosphatidylinositol-3-kinase (PI3K), blocked Bcl-3
expression in platelets adherent to immobilized fibrinogen
(not shown), as they do in thrombin-stimulated aggregated
platelets (Weyrich et al., 1998).
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We then used an alternative strategy to ask if engagement of integrin aIIbb3 delivers outside-in signals to the
translation pathway that regulates synthesis of Bcl-3. mAb
D3GP3 is directed against the b3 chain of the integrin
aIIbb3 heterodimer and induces a conformational change
that makes the integrin competent to bind fibrinogen and
mediate aggregation in the absence of thrombin or another stimulus (Kouns et al., 1990; Kouns and Jennings,
1991). We found that incubation of platelets with mAb
D3GP3 resulted in their aggregation (not shown), as previously reported, and also triggered synthesis of Bcl-3 (Fig. 7
b). An isotype-matched antibody against another protein
on the platelet plasma membrane, PECAM-1 (CD31), did
not induce Bcl-3 synthesis (not shown). When examined
by immunocytochemistry, Bcl-3 was predominantly located in aggregated platelets in suspensions treated with
D3GP3, with few single platelets showing staining (not
shown). The accumulation of Bcl-3 in platelets incubated
with mAb D3GP3 was not as great as that in platelets
stimulated with thrombin in parallel (Fig. 7 b), consistent
with the fact that the antibody induces submaximal aggregation under these conditions (Kouns et al., 1990) (our experiments not shown). Platelets treated with mAb D3GP3
bind exogenously added fibrinogen in an enhanced fashion (Kouns et al., 1990). When we added soluble fibrinogen to the incubation, the accumulation of Bcl-3 was enhanced in platelets incubated with D3GP3 (Fig. 7 b).
Exogenous soluble fibrinogen did not induce Bcl-3 synthesis in platelets incubated with the control mAb against
PECAM-1 (not shown).

Collagen Triggers Bcl-3 Synthesis by Human Platelets
Collagen is recognized by integrin a2b1 as well as by other
adhesion molecules on platelets, and treatment of isolated
platelets with collagen in solution induces activation of intracellular kinases and aggregation equivalent in magnitude to that triggered by thrombin (Lipfert et al., 1992;
Shattil et al., 1994). We found that collagen in solution
induced synthesis of Bcl-3 in a concentration-dependent
fashion (Fig. 8 a). In addition, we found that platelets adherent to immobilized collagen synthesized Bcl-3 (Fig. 8
b). The accumulation of Bcl-3 in platelets adherent to immobilized collagen was inhibited by a blocking antibody
against the integrin a2 subunit (not shown) and also by
mAb 7E3 (see above) (Fig. 8 b) but not by a control mAb
against avb3 (not shown). The latter findings are consistent
with a previous report that mAb 7E3 and an antibody
against a2b1 integrin each inhibited outside-in signaling of
platelets when the cells adhered to an immobilized collagen matrix (Haimovich et al., 1993). mAb 10E5 also
blocked synthesis of Bcl-3 under similar conditions (Fig. 8
b). Thus, engagement of integrin a2b1 and/or other surface
receptors for collagen together with integrin aIIbb3 may
mediate signaling of translational events leading to Bcl-3
synthesis in a costimulatory fashion.

Figure 8. Collagen induces synthesis of Bcl-3 in human platelets.
(a) Collagen in solution induces Bcl-3 synthesis by human platelets. Platelets were isolated as described in Materials and Methods and incubated in suspension with collagen in the concentrations shown for 1 h at 378C. Synthesis of Bcl-3 protein was
examined by Western analysis. Collagen in solution induced Bcl-3
expression in three additional experiments. (b) Adhesion of
platelets to immobilized collagen induces Bcl-3 synthesis. Platelets were pretreated with control buffer, mAb 10E5, or mAb 7E3
as described in Fig. 4 and Materials and Methods and then were
incubated on immobilized collagen or on immobilized albumin
for 1 h at 378C. Accumulation of Bcl-3 was examined by Western
analysis as described in Materials and Methods. This result is representative of three experiments.

The flow of genetic information is regulated at sequential checkpoints that, together, provide precise control of
the expression of protein products (Darnell, 1982; Kozak,

1991). Here we show that integrin aIIbb3 regulates translation of a marker protein, Bcl-3, in thrombin-stimulated aggregated platelets. Integrin aIIbb3 is the principle integrin
of human platelets and is a herald member of the integrin
family that has yielded many insights into the structure
and function of these adhesion proteins (Phillips et al.,
1991; Hynes, 1992; Shattil et al., 1994; Shattil et al., 1998).
We also found that outside-in signals delivered via integrin
aIIbb3 trigger Bcl-3 synthesis when the integrin heterodimer is engaged by immobilized ligand or a function-perturbing antibody. Our findings raise the possibility that a
general mechanism by which integrins regulate gene expression is by interacting at posttranscriptional checkpoints, in addition to mediating nuclear signaling and transcriptional events. It has been suggested previously that b1
integrins on leukocytes may influence posttranscriptional
steps (Mondal et al., 1995). Also, mechanical signaling via
engaged b1 integrins may orchestrate local accumulation
of mRNA and ribosomes in the region of focal adhesion
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complexes (Chicurel et al., 1998). However, our findings
provide the first evidence that outside-in signaling via a
specific integrin heterodimer regulates expression of protein products in the absence of nuclear effects.
Human platelets may be a particularly informative system in which to study adhesion-dependent signaling of
translation in a primary cell type, and mechanisms elucidated in platelets may also reflect similar processes at the
earlier, nucleated, megakaryocyte stage (Weyrich et al.,
1998). Platelets have ribosomes and other components required for protein synthesis and carry stable mRNA transcripts (Warshaw et al., 1967; Morgenstern, 1980; Belloc
et al., 1982; Kieffer et al., 1987; Newman et al., 1988; Roth
et al., 1989; Power et al., 1995). Multiple new proteins are
synthesized in thrombin-stimulated platelets and in platelets adherent to immobilized fibrinogen; this synthesis is
interrupted by puromycin and cycloheximide and, for a
subset of these proteins, by rapamycin (Weyrich, 1998; and
our unpublished observations). To date, we have identified Bcl-3 as one of the newly synthesized products and
five others as proteins that regulate or are involved in cytoskeletal interactions (Weyrich A.S., N.D. Tolley, M.L.
Wade, T.M. McIntyre, S.M. Prescott, Z. Wu, and G.A.
Zimmerman, manuscript in preparation). Although mitochondrial transcription occurs in platelets (Agam et al.,
1976), Bcl-3 is translated from preformed mRNA and the
transcriptional inhibitor actinomycin D does not prevent
synthesis (Weyrich et al., 1998). Platelets contain key enzymes in the specialized mTOR pathway that controls
translation of a subset of mRNAs with specific structural
features (Brown and Schreiber, 1996; Thomas and Hall,
1997), including the mRNA for Bcl-3 (Weyrich et al.,
1998). Current evidence from cell lines and transfected cell
models indicate that activity in this pathway is initiated by
a signal at the plasma membrane followed by a cascade involving PI3K and 3-phosphoinositide-dependent protein
kinase 1 (PDK1) and culminating in phosphorylation of
the translation repressor eIF4E-binding protein 1 (4EBP-1),
causing it to dissociate from eukaryotic translation initiation factor 4E (eIF4E) and allowing cap-dependent translation to proceed (Sonenberg and Gingras, 1998). Phosphorylation and activation of the ribosomal S6 kinase, p70
S6 kinase (p70S6K), also occurs. In previous studies of lymphocytic cell lines and fibroblasts, this pathway was shown
to be triggered by growth factors and mitogens (reviewed
in Brown and Schreiber, 1996; Thomas and Hall, 1997;
Peterson and Schreiber, 1998; Sonenberg and Gingras,
1998). In aggregating platelets, PI3K is triggered in an
adhesion-dependent fashion and PDK1 is also present
(Clark and Brugge, 1995; Banfic et al., 1998a,b). Inhibitors
of PI3K block synthesis of Bcl-3 in thrombin-stimulated
aggregated platelets (Weyrich et al., 1998) and in platelets
adherent to immobilized fibrinogen (this study). In addition, p70S6K is present in human platelets (Papkoff et al.,
1994) and is activated when they aggregate in response
to thrombin (Weyrich, A.S., unpublished experiments).
4EBP-1 is also phosphorylated in thrombin-stimulated
platelets and this event and the synthesis of Bcl-3 are
blocked by inhibitors of PI3K and by rapamycin (Weyrich
et al., 1998). Thus, platelets have critical enzymatic and
regulatory molecules that are required for translation control, including components of the mTOR pathway, and the

activities of these systems are influenced by outside-in signals.
Using blocking antibodies, competitive peptides, and
deficient platelets from a subject with Glanzmann thrombasthenia, we found that engagement of integrin aIIbb3
regulates Bcl-3 synthesis in aggregating platelets stimulated by thrombin. Thus, signals transmitted by integrin
aIIbb3 are linked to translation control pathways. We also
found that ligation of integrin aIIbb3 by immobilized fibrinogen or binding of a conformation-altering antibody induces synthesis of Bcl-3 in the absence of thrombin stimulation. These experiments and our previous observations
(Weyrich et al., 1998) indicate that engagement of integrin
aIIbb3 is sufficient to signal activation of translational pathways and synthesis of a variety of proteins. Binding of fibrinogen to integrin aIIbb3 in the presence of an activating
“LIBS” anti-b3 antibody triggers PI3K and apparent PDK1
activities, responses that require platelet–platelet contact
and aggregation to be maximal (Banfic et al., 1998a,b).
Thus, engagement of integrin aIIbb3 can activate key enzymes in the transduction cascade that relay signals from
the plasma membrane to translational pathways (see above).
Whether there are intracellular signaling cascades that are
specific to integrin aIIbb3 (Banfic et al., 1998a) is unknown.
In other systems, integrins and growth factors or mitogens
use common, rather than unique, intracellular mechanisms
to trigger gene expression (Juliano, 1996; Howe et al.,
1998). How integrin aIIbb3 interfaces with downstream
components of the translation control pathway that regulate phosphorylation of 4EBP1 and p70S6K activation is
also currently unknown. In a previous study, adhesion of a
cell line to immobilized fibronectin, laminin, or vitronectin
activated p70S6K, implying that regulation of this enzyme is
linked to engagement of integrins of both the b1 and b3
classes (Malik and Parsons, 1996). Additional experiments
indicated that focal adhesion kinase was partially required
for p70S6K activation. Whether focal adhesion kinase, which
is signaled by integrin aIIbb3 engagement (Lipfert et al.,
1992; reviewed in Shattil et al., 1994; reviewed in Clark
and Brugge, 1995; Lyman et al., 1997; and reviewed in
Shattil et al., 1998), is involved in p70S6K activation and
translational regulation in platelets remains to be explored.
In cell–cell interactions, signals delivered through adhesion molecules are integrated with signals from surface receptors, such as those for growth factors or chemokines, to
yield qualitatively distinct responses (Weyrich et al., 1996;
Zimmerman et al., 1996). Signals delivered by integrins
and growth factors converge and are integrated in this
fashion (reviewed in Schwartz et al., 1995; Juliano, 1996;
Sastry and Horwitz, 1996). Our finding that Bcl-3 expression in platelets is induced by thrombin stimulation raises
the possibility that outside-in signals transmitted by engagement of integrin aIIbb3 interface and are integrated
with those generated by ligation of the thrombin receptor
resulting in translation of mRNAs. The thrombin receptor
and integrin aIIbb3 transmit convergent signals to other response pathways in human platelets (Ferrell and Martin,
1989; Golden et al., 1990; Clark et al., 1994; Shattil et al.,
1994; Cichowski et al., 1996). In our experiments, expression of Bcl-3 in thrombin-activated platelets required engagement of integrin aIIbb3 at concentrations of thrombin
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(0.01–0.1 U/ml) that triggered maximal or near-maximal
platelet aggregation, and was blocked by inhibitory antibodies or peptides against aIIbb3 (see Results). The results
argue that at these concentrations ligation of the thrombin
receptor is not sufficient to induce translation. At higher concentrations of thrombin, there appeared to be an aIIbb3independent mechanism of signaling when platelets from
a subject with Glanzmann thrombasthenia were studied
(Fig. 6). This is potentially due to differential signaling
through other receptors on platelets that recognize thrombin (Schmidt et al., 1998). Alternatively, this may represent the activity of a small number of residual copies of integrin aIIbb3 on the platelets that we used for this study
(Jin et al., 1996).
In addition to integrating of signals delivered via receptors for mitogens and growth factors, integrins of different
classes may also signal cooperatively (Schwartz et al.,
1995; Juliano, 1996). Our experiments in which adhesion
of platelets to immobilized collagen induced synthesis of
Bcl-3 (Results and Fig. 8) indicate that integrin aIIbb3 and
integrin a2b1 cooperatively signal translation events. We
found that an antibody against the a2 subunit of a2b1 integrin, which recognizes collagen, and mAb 7E3 and 10E5,
which block ligand binding by integrin aIIbb3, each inhibited Bcl-3 synthesis in platelets that adhered to immobilized collagen matrices (Results). One explanation for this
experimental outcome is that adhesion of individual platelets to immobilized collagen caused outside-in signaling
via integrin a2b1 and triggered degranulation and local secretion of fibrinogen, with secondary formation of microaggregates caused by binding of fibrinogen to integrin
aIIbb3 on adjacent platelets. Haimovich et al. (1993) reported that microaggregate formation occurs when platelet suspensions are incubated on immobilized collagen and
that this is blocked by mAb 7E3. Thus, it is possible that
engagement of integrin aIIbb3 by endogenously released
fibrinogen alone signals expression of Bcl-3 under these
conditions. Alternatively, engagement of integrin a2b1
may signal directly to the mTOR pathway when platelets
bind to immobilized collagen and additionally triggers local secretion of fibrinogen and engagement of integrin
aIIbb3, concomitantly inducing translation of Bcl-3. Although these two possibilities cannot be resolved yet, our
results are consistent with cooperative interaction of the
two platelet integrins in regulating translational events.
Additional evidence for cooperative interaction between
integrins aIIbb3 and a2b1 has also been reported (Coller et
al., 1989; Lipfert et al., 1992; Savage et al., 1998). Whether
other receptors for collagen (Shattil et al., 1994; Savage et al.,
1998; Watson and Gibbins, 1998) also signal translation in
adherent platelets is unknown at this time.
Our finding that engagement of integrins regulates synthesis of proteins in platelets (Results and Weyrich et al.,
1998) suggests that control of translation is a general
mechanism by which integrins and other classes of adhesion molecules influence gene expression. Adhesion-dependent signaling, a process by which integrins and other
adhesion molecules can specifically modulate or induce
synthesis of particular gene products, adds spatial regulation to this process (Juliano, 1996; Schwartz et al., 1996;
Zimmerman et al., 1996). In addition to spatial regulation,
activation of translation pathways by outside-in signals de-
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livered through integrins or other adhesion molecules can
rapidly induce synthesis of proteins from preformed mRNA,
influencing the temporal sequence of expression of gene
products. Specific modulation by integrins of translation
checkpoints, which are downstream of transcription, mRNA
processing, nuclear export, mRNA degradation, also adds
precision and variety in signaling of gene expression that
would not be available if transcription were the only point
of influence (Darnell, 1982). Our ongoing studies indicate
that translation control occurs when other adhesion molecules besides integrins are engaged (Mahoney, T.S., A.S.
Weyrich, G.A. Zimmerman, T.M. McIntyre, S.M. Prescott, manuscript in preparation), suggesting that signaling
to translational control pathways is a general mechanism
of adhesion-dependent regulation of gene expression.
We thank Jeanne Falk, Donnie Benson, and Wenhua Li for excellent
technical assistance. We also thank Barry S. Coller, Lisa Jennings, Tom
Gadek, Stanley Hollenbach, and Susan Tam for the gifts of important reagents. We are grateful to our colleagues at the CVRTI for their helpful
comments and critical reading of the manuscript, to Cletus D’Souza for
performing protein determinations, and Diana Lim and Richard Kuenzler
for preparation of figures. We appreciate the help of Leona Montoya and
Michelle Bills in preparation of the manuscript.
This work was supported by the Nora Eccles Treadwell Foundation,
and the Richard A. and Nora Eccles Harrison Fund for Cardiovascular
Research, the National Institutes of Health (HL44525), and the Wellcome
Trust (UK). Dr. Ravinder Pabla is a Wellcome International Traveling
Fellow (grant 046937/Z/96/Z/).
Received for publication 12 August 1998 and in revised form 24 November 1998.
References

let GPIa/IIa and an indirect interaction with platelet GPIIb/IIIa mediated by
adhesive proteins. Blood. 74:182–192.
Darnell, J.E., Jr. 1982. Variety in the level of gene control in eucaryotic cells.
Nature. 297:365–371.
Du, X., E.F. Plow, A.L. Frelinger III, T.E. O’Toole, J.C. Loftus, and M.H.
Ginsberg. 1991. Ligands “activate” integrin aIIbb3 (platelet GPIIb-IIIa). Cell.
65:409–416.
Ferrell, J.E., Jr., and G.S. Martin. 1989. Tyrosine-specific protein phosphorylation is regulated by glycoprotein IIb-IIIa in platelets. Proc. Natl. Acad. Sci.
USA. 86:2234–2238.
Fitzgerald, L.A., and D.R. Phillips. 1985. Calcium regulation of the platelet
membrane glycoprotein IIb-IIIa complex. J. Biol. Chem. 260:11366–11374.
Gawaz, M.P., J.C. Loftus, M.L. Bajt, M.M. Frojmovic, E.F. Plow, and M.H.
Ginsberg. 1991. Ligand bridging mediates integrin aIIbb3 (platelet GPIIBIIIA) dependent homotypic and heterotypic cell–cell interactions. J. Clin.
Invest. 88:1128–1134.
George, J.N., J.P. Caen, and A.T. Nurden. 1990. Glanzmann’s thrombasthenia:
the spectrum of clinical disease. Blood. 75:1383–1395.
Golden, A., J.S. Brugge, and S.J. Shattil. 1990. Role of platelet membrane glycoprotein IIb-IIIa in agonist-induced tyrosine phosphorylation of platelet
proteins. J. Cell Biol. 111:3117–3127.
Haimovich, B., L. Lipfert, J.S. Brugge, and S.J. Shattil. 1993. Tyrosine phosphorylation and cytoskeletal reorganization in platelets are triggered by interaction of integrin receptors with their immobilized ligands. J. Biol. Chem. 268:
15868–15877.
Hamburger, S.A., and R.P. McEver. 1990. GMP-140 mediates adhesion of stimulated platelets to neutrophils. Blood. 75:550–554.
Howe, A., A.R.E. Aplin, S.K. Alahari, and R.L. Juliano. 1998. Integrin signaling and cell growth control. Curr. Opin. Cell Biol. 10:220–231.
Hynes, R.C. 1992. Integrins: versatility, modulation, and signaling in cell adhesion. Cell. 69:11–25.
Jin, Y., H.C. Dietz, R.A. Montgomery, W.R. Bell, I. McIntosh, B. Coller, and
P.F. Bray. 1996. Glanzmann thrombasthenia. Cooperation between sequence variants in Cis during splice site selection. J. Clin. Invest. 98:1745–
1754.
Juliano, R. 1996. Cooperation between soluble factors and integrin-mediated
cell anchorage in the control of cell growth and differentiation. Bioessays.
18:911–917.
Juliano, R.L., and S. Haskill. 1993. Signal transduction from the extracellular
matrix. J. Cell Biol. 120:577–585.
Kameyoshi, Y., A. Dorschner, A.I. Mallet, E. Christophers, and J.M. Schroder.
1992. Cytokine RANTES released by thrombin-stimulated platelets is a potent attractant for human eosinophils. J. Exp. Med. 176:587–592.
Kieffer, N., J. Guichard, J.-P. Farcet, W. Vainchenker, and J. Breton-Gorius.
1987. Biosynthesis of major platelet proteins in human blood platelets. Eur.
J. Biochem. 164:189–195.
Kouns, W.C., and L.K. Jennings. 1991. Activation-independent exposure of the
GPIIb/IIIa fibrinogen receptor. Thromb. Res. 63:343–354.
Kouns, W.C., C.D. Wall, M.M. White, C.F. Fox, and L.K. Jennings. 1990. A
conformation-dependent epitope of human platelet glycoprotein IIIa. J.
Biol. Chem. 265:20594–20601.
Kozak, M. 1991. An analysis of vertebrate mRNA sequences: intimations of
translational control. J. Cell Biol. 115:887–903.
Lipfert, L., B. Haimovich, M.D. Schaller, B.S. Cobb, J.T. Parsons, and J.S.
Brugge. 1992. Integrin-dependent phosphorylation and activation of the protein tyrosine kinase pp125FAK in platelets. J. Cell Biol. 119:905–912.
Lyman, S., A. Gilmore, K. Burridge, S. Gidwitz, and G.C. White II. 1997. Integrin-mediated activation of focal adhesion kinase is independent of focal adhesion formation or integrin activation. Studies with activated and inhibitory
b3 cytoplasmic domain mutants. J. Biol. Chem. 272:22538–22547.
Malik, R.K., and J.T. Parsons. 1996. Integrin-dependent activation of the p70 ribosomal S6 kinase signaling pathway. J. Biol. Chem. 271:29785–29791.
Modur, V., M.J. Feldhaus, A.S. Weyrich, D.L. Jicha, S.M. Prescott, G.A. Zimmerman, and T.M. McIntyre. 1997. Oncostatin M is a proinflammatory mediator. In vivo effects correlate with endothelial cell expression of inflammatory cytokines and adhesion molecules. J. Clin. Invest. 100:158–168.
Mondal, K., A.K. Lofquist, J.M. Watson, J.S. Morris, L.K. Price, and J.S.
Haskill. 1995. Adhesion and direct integrin engagement differentially regulate gene transcription, transcript stabilization and translation. Biochem.
Soc. Trans. 23:460–464.
Morgenstern, E. 1980. Ultracytochemistry of human blood platelets. Prog. Histochem. Cytochem. 12:1–86.
Newman, P.J., and M. Poncz. 1995. Inherited disorders of platelets. In The Metabolic and Molecular Bases of Inherited Disease. 7th edition. C.R. Scriver,
A.L. Beaudet, W.S. Sly, D. Valle, J.B. Stanbury, J.B. Wyngaarden, and D.S.
Fredrickson, editors. McGraw-Hill, Inc., New York. 3335–3366.
Newman, P.J., J. Gorski, G.C. White II, S. Gidwitz, C.J. Cretney, and R.H. Aster. 1988. Enzymatic amplification of platelet-specific messenger RNA using
the polymerase chain reaction. J. Clin. Invest. 82:739–743.
Ohno, H., G. Takimoto, and T.W. McKeithan. 1990. The candidate proto-oncogene Bcl-3 is related to genes implicated in cell lineage determination and
cell cycle control. Cell. 60:991–997.
Pan, J., and R.P. McEver. 1995. Regulation of the human P-selectin promoter
by Bcl-3 and specific homodimeric members of the NF-kB/Rel family. J.
Biol. Chem. 270:23077–23083.
Papkoff, J., R.H. Chen, J. Blenis, and J. Forsman. 1994. P42 mitogen-activated
protein kinase and p70 ribosomal S6 kinase are selectively phosphorylated

and activated during thrombin-induced platelet activation and aggregation.
Mol. Cell Biol. 14:463–472.
Peterson, R.T., and S.L. Schreiber. 1998. Translation control: connecting mitogens and the ribosome. Curr. Biol. 8:R248–R250.
Phillips, D.R., I.F. Charo, and R.M. Scarborough. 1991. GPIIb-IIIa: the responsive integrin. Cell. 65:359–362.
Power, C.A., J.M. Clemetson, K.J. Clemetson, and T.N.C. Wells. 1995.
Chemokine and chemokine receptor mRNA expression in human platelets.
Cytokine. 7:479–482.
Pursuit Trial Investigators. 1998. Inhibition of platelet glycoprotein IIb/IIIa
with eptifibatide in patients with acute coronary syndromes. N. Engl. J. Med.
339:436–443.
Reverter, J.C., S. Béguin, H. Kessels, R. Kumar, H.C. Hemker, and B.S. Coller.
1996. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for
the effect of c7E3 Fab treatment on acute thrombosis and clinical restenosis.
J. Clin. Invest. 98:863–874.
Roth, G.J., M.J. Hickey, D.W. Chung, and D.D. Hickstein. 1989. Circulating
human blood platelets retain appreciable amounts of poly (A)1 RNA. Biochem. Biophys. Res. Commun. 160:705–710.
Sastry, S.K., and A.F. Horwitz. 1996. Adhesion-growth factor interactions during differentiation: an integrated biological response. Dev. Biol. 180:455–467.
Savage, B., and Z.M. Ruggeri. 1991. Selective recognition of adhesive sites in
surface-bound fibrinogen by glycoprotein IIb-IIIa on nonactivated platelets.
J. Biol. Chem. 266:11227–11233.
Savage, B., F. Almus-Jacobs, and Z.M. Ruggeri. 1998. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under
flow. Cell. 94:657–666.
Scarborough, R.M., J.W. Rose, M.A. Hsu, D.R. Phillips, V.A. Fried, A.M.
Campbell, L. Nannizzi, and I.F. Charo. 1991. Barbourin: a GPIIb-IIIa specific integrin antagonist from the venom of Sistrurus M. Barbouri. J. Biol.
Chem. 266:9359–9362.
Scarborough, R.M., M.A. Naughton, W. Teng, J.W. Rose, D.R. Phillips, L.
Nannizzi, A. Arfsten, A.M. Campbell, and I.F. Charo. 1993. Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa. J. Biol. Chem. 268:1066–1073.
Schmidt, V.A., W.C. Nierman, D.R. Maglott, L.D. Cupit, K.A. Moskowitz, J.A.
Wainer, and W.R. Bahou. 1998. The human proteinase-activated receptor-3
(PAR-3) gene. Identification within a PAR gene cluster and characterization in vascular endothelial cells and platelets. J. Biol. Chem. 273:15061–
15068.
Schulman, S.P., P.J. Goldschmidt-Clermont, E.J. Topol, R.M. Califf, F.I.
Navetta, J.T. Willerson, N.C. Chandra, A.D. Guerci, J.J. Ferguson, R.A.
Harrington, et al. 1996. Effects of integrilin, a platelet glycoprotein IIb/IIIa
receptor antagonist, in unstable angina. A randomized multicenter trial. Circulation. 94:2083–2089.
Schwartz, M.A., M.D. Schaller, and M.H. Ginsberg. 1995. Integrins: emerging
paradigms of signal transduction. Annu. Rev. Cell Dev. Biol. 11:549–599.
Schwartz, M.A., D. Toksoz, and R. Khosrari-Far. 1996. Transformation by Rho
exchange factor oncogenes is mediated by activation of an integrin-dependent pathway. EMBO (Eur. Mol. Biol. Organ.) J. 15:6525–6530.
Shattil, S.J., and M.H. Ginsberg. 1997. Integrin signaling in vascular biology. J.
Clin. Invest. 100:1–5.
Shattil, S.J., L.F. Brass, J.S. Bennett, and P. Pandhi. 1985. Biochemical and
functional consequences of dissociation of the platelet membranes glycoprotein IIb-IIIa complex. Blood. 66:92–98.
Shattil, S.J., M.H. Ginsberg, and J.S. Brugge. 1994. Adhesive signaling in platelets. Curr. Opin. Cell Biol. 6:695–704.
Shattil, S.J., H. Kashiwagi, and N. Pampori. 1998. Integrin signaling: the platelet
paradigm. Blood. 91:2645–2657.
Sonenberg, N., and A.-C. Gingras. 1998. The mRNA 59 cap-binding protein
eIF4E and control of cell growth. Curr. Opin. Cell Biol. 10:268–275.
Thomas, G., and M.N. Hall. 1997. TOR signalling and control of cell growth.
Curr. Opin. Cell Biol. 9:782–787.
Wang, R., S.J. Shattil, D.R. Ambruso, and P.J. Newman. 1997. Truncation of
the cytoplasmic domain of b3 in a variant form of Glanzmann thrombasthenia abrogates signaling through the integrin aIIbb3 complex. J. Clin. Invest.
100:2393–2403.
Warshaw, A.L., L. Laster, and N.R. Schulman. 1967. Protein synthesis by human platelets. J. Biol. Chem. 242:2094–2097.
Watson, S.P., and J. Gibbins. 1998. Collagen receptor signaling in platelets: extending the role of the ITAM. Immunol. Today. 19:260–264.
Weyrich, A.S., X.-L. Ma, D.J. Lefer, K.H. Albertine, and A.M. Lefer. 1993. In
vivo neutralization of P-selectin protects feline heart and endothelium in
myocardial ischemia and reperfusion injury. J. Clin. Invest. 91:2620–2629.
Weyrich, A.S., M.R. Elstad, R.P. McEver, T.M. McIntyre, K.L. Moore, J.H.
Morrissey, S.M. Prescott, and G.A. Zimmerman. 1996. Activated platelets
signal chemokine synthesis by human monocytes. J. Clin. Invest. 97:1525–
1534.
Weyrich, A.S., D.A. Dixon, R. Pabla, M.R. Elstad, T.M. McIntyre, S.M. Prescott, and G.A. Zimmerman. 1998. Signal-dependent translation of a regulatory protein, Bcl-3, in activated human platelets. Proc. Natl. Acad. Sci. USA.
95:5556–5561.
Williams, M.J., X. Du, J.C. Loftus, and M.H. Ginsberg. 1995. Platelet adhesion
receptors. Semin. Cell Biol. 6:305–314.
Zimmerman, G.A., T.M. McIntyre, and S.M. Prescott. 1996. Adhesion and signaling in vascular cell–cell interactions. J. Clin. Invest. 98:1699–1702.

The Journal of Cell Biology, Volume 144, 1999

184

